NeurologyOnline.net

Neurology Xagena

Researchers from the University of Sheffield in collaboration with researchers from the University of York have discovered a drug which has already been in use for decades to treat liver disease. The ...


New results from a prespecified interim analysis of PRIME, the phase 1b placebo-controlled study of Aducanumab in patients with prodromal or mild Alzheimer’s disease, were presented at the Alzheimer’s ...


New results from a 684-subject phase 2b clinical trial evaluating RVT-101, as an adjunctive therapy to Donepezil in patients with mild-to-moderate Alzheimer's disease, were presented at the 2015 Alzhe ...


Multiple sclerosis ( MS ) is a chronic disabling disease of the central nervous system ( CNS ), affecting more than 2 million people worldwide. The disease usually starts in early adulthood, but the ...


Therapeutic repair of myelin disorders may be limited by the relatively slow rate of human oligodendrocyte differentiation. To identify appropriate pharmacological targets with which to accelerate ...


Roche has announced positive results from two pivotal studies evaluating the investigational medicine Ocrelizumab compared with Interferon beta-1a ( Rebif ), a standard-of-care therapy, in people with ...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa ) in March 2011, and three more NOACs, Rivaroxaban ( Xarelto ), Apixaban ( Eli ...


Although multiple sclerosis is thought to represent an excessive and inappropriate immune response to several central nervous system ( CNS ) autoantigens, increasing evidence also suggests that multip ...


Multiple sclerosis is triggered by self-reactive T cells that successfully infiltrate the brain and spinal cord where they launch an aggressive autoimmune attack against myelin. Over time, the resulti ...


Modern scientific understanding has considered multiple sclerosis to be a disease controlled by the T cell, a type of white blood cell. Research has shown that in multiple sclerosis, T cells inappropr ...


The phase 3 ASCEND study investigating Natalizumab ( Tysabri ) in the treatment of secondary progressive multiple sclerosis ( SPMS ) did not achieve its primary and secondary endpoints. During the stu ...


The purpose was to report the effects of delayed-release Dimethyl fumarate ( DMF; also known as gastro-resistant DMF ) on the number of relapses requiring intravenous ( IV ) steroids and multiple scle ...


Uric acid may lessen women’s disability after stroke, according to new research published in Stroke, journal of American Heart Association ( AHA ). High levels of Uric acid can lead to kidney ston ...


Researchers have analyzed the evolution of non-motor symptoms and patients’ and neurologists’ clinical global impression ( CGI ) in advanced Parkinson's disease patients treated with Levodopa–Carbidop ...


Extensive published evidence supports the use of subcutaneously-administered Apomorphine as an effective therapy for Parkinson's disease ( PD ) but to date no consensus recommendations have been avail ...